Quick Answer
ZEVRA THERAPEUTICS, INC. reported Diluted EPS of $1.35 per share for fiscal year 2025.
ZEVRA THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.35 | +159.2% |
| 2024 | -$2.28 | -8.1% |
| 2021 | -$2.11 | +34.3% |
| 2020 | -$3.21 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.01 | +98.6% | -100.8% |
| June 30, 2025 | $1.21 | +352.1% | +275.4% |
| September 30, 2024 | -$0.69 | — | -43.7% |
| June 30, 2024 | -$0.48 | — | -700.0% |
| September 30, 2021 | -$0.06 | +91.2% | +85.0% |
| June 30, 2021 | -$0.40 | -290.5% | +83.9% |
| March 31, 2021 | -$2.49 | -29.7% | -266.2% |
| September 30, 2020 | -$0.68 | -1233.3% | -423.8% |
- ZEVRA THERAPEUTICS, INC. showed an increase of +159.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, ZEVRA THERAPEUTICS, INC.’s diluted eps has grown by 142.1% (from $3.21 per share (loss) to $1.35 per share).
- The most recent figure is from ZEVRA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: